Navigation Links
Researchers find public sector research responsible for many new drug discoveries
Date:2/9/2011

(Boston) - Researchers from Boston University School's of Medicine (BUSM), Management (SMG) and Law (LAW), along with collaborators from the National Institutes of Health, believe that public-sector research has had a more immediate effect on improving public health than was previously realized. The findings, which appear as a Special Article in the February 10th issue of The New England Journal of Medicine, have economic and policy implications.

Historically, public sector research institutions (PSRI) have not participated in any major way in the downstream, applied phase of drug discovery, in which the actual products are discovered and patented. However, in the mid-1970s, the newly emerging tools of biotechnology allowed PSRIs to create and patent biologic drug candidates and discover and patent small molecule drugs. At that time, all products created in academic institutions were owned by the government, which granted only nonexclusive licenses.

In 1980, Congress passed two pieces of legislation that transformed the ownership, management and transfer of intellectual property that is created by PSRIs. First, the BayhDole Act allowed universities, nonprofit research institutes and teaching hospitals to own the intellectual property resulting from federally funded research and to license it according to terms of their choosing. Second, the StevensonWydler Technology Innovation Act as amended by the Federal Technology Transfer Act of 1986, provided a corresponding authority to federal laboratories. Under this new approach, inventions that arose from PSRIs, in addition to being freely published in the scientific literature, could also be converted into intellectual property and transferred through license agreements to the private sector for commercialization and public use.

In order to quantitate the contribution of public-sector research to the applied-research phase of drug discovery, the researchers identified new drugs and vaccines approved by the Food and Drug Administration (FDA) and classified them according to their therapeutic category and potential therapeutic effect. The researchers found that during the past 30 years, 153 new FDA-approved drugs, vaccines, or new indications for existing drugs were discovered through research carried out in PSRIs. These drugs included 93 small-molecule drugs, 36 biologic agents, 15 vaccines, eight in-vivo diagnostic materials, and one over-the-counter drug. Current and former Boston University researchers were responsible for four of those 153 new drugs, one of which was developed based on research conducted at the University and Boston Medical Center.

"We believe that our study supports the concept that the emergence of biotechnology in the mid-1970s, combined with policy changes implemented in the early 1980s regarding the ownership and management of the intellectual property of PSRIs, allowed these institutions to play an important role in the downstream, applied phase of drug discovery," said lead author Ashley J. Stevens, D.Phil (Oxon), CLP, a lecturer at BUSM as well as Special Assistant to the Vice President for Research, Technology Development and a Senior Research Associate, ITEC, SMG. He is also currently the President of the Association of University Technology Managers.

According to the researchers, the data also suggest that PSRIs tend to discover drugs that have a disproportionately important clinical effect. "Slightly over half of these drugs were for the treatment or prevention of cancer or infectious diseases. Furthermore, drugs discovered by PSRIs received Priority Review by the FDA at twice the rate as for all FDA drug approvals, indicating that PSRI discovered drugs were expected to have a disproportionately high therapeutic impact," added Stevens.

"We hope our research will help inform the amplified conversation taking place around innovation policy in the US and abroad," said co-author Jonathan Jensen, MBA, Director, Business Development, Technology Development at Boston University. "The factors involved in bringing a single one of these drugs to market are complex. With a more comprehensive understanding of the contribution of the public sector to the development of FDA approved drugs, as our work attempts to establish, one can better appreciate and further study the factors involved in the transfer of knowledge from the public to the private sector," he added.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. What makes fructose fattening? OHSU researchers find some answers in the brain
2. Researchers: Elderly patients 4 times more likely to die from treatment complications
3. Researchers identify the genotype of disorders causing cardiac sudden death syndrome
4. Researchers predict nearly 1.3 million cancer deaths in Europe in 2011
5. Researchers develop outline that may help weigh benefits of new imaging technologies
6. Project connects researchers, Latino communities to prevent cancer
7. Researchers get a grip on nervous systems receptors
8. U-M Medical School researchers set new record in NIH funding: $368.7 million
9. UNC researchers developing computer models for pediatric airway problems
10. Rheumatoid arthritis researchers redefine remission
11. Researchers lead search for better drug-addiction treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... After a long health ordeal ... new lease on life with assistance from CreditAssociates. CreditAssociates provides debt relief and ... unsecured debt. The senior is one of the satisfied clients who expressed their ...
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE ... Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, California, who will ... Administration at St. Thomas University in Miami, Florida, was selected from a pool ...
(Date:9/22/2017)... Chicago, IL (PRWEB) , ... September 22, 2017 , ... ... founding attorney Richard L. Pullano has been selected to serve as President ... Association’s 50th President at the Installation and Award Dinner hosted by the NSBA at ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... supplement produced by Native Remedies that helps promote pancreatic health and regulate ... individuals. However, some prescription-based approaches can have negative side effects, and with the ...
(Date:9/22/2017)... ... September 22, 2017 , ... "Success ... the world of Alzheimer’s. Alzheimer’s is a disease estimated to affect the lives ... information published by the Alzheimer’s Association, a leading voice in the fight for ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company ... Novartis Pharma AG to distribute NuvoAir,s spirometry technology to physicians ... spirometry platform and Novartis, commitment to address the unmet medical ... ... "We ...
(Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
(Date:9/5/2017)... KEYSTONE, Colo. , Sept. 5, 2017 ... their XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party ... update existing CT scanners and allows compliance with current ... The Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically ... notifications and alerts of potential radiation doses over a ...
Breaking Medicine Technology: